ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Chloramphenicol: Drug information

Chloramphenicol: Drug information
2024© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
For additional information see "Chloramphenicol: Patient drug information" and "Chloramphenicol: Pediatric drug information"

For abbreviations, symbols, and age group definitions show table
ALERT: US Boxed Warning
Blood dyscrasias:

Serious and fatal blood dyscrasias (aplastic anemia, hypoplastic anemia, thrombocytopenia, and granulocytopenia) are known to occur after the administration of chloramphenicol. In addition, there have been reports of aplastic anemia attributed to chloramphenicol which later terminated in leukemia. Blood dyscrasias have occurred after both short-term and prolonged therapy with this drug. Chloramphenicol must not be used when less potentially dangerous agents will be effective. It must not be used in the treatment of trivial infections or where it is not indicated, as in colds, influenza, infections of the throat; or as a prophylactic agent to prevent bacterial infections.

It is essential that adequate blood studies be made during treatment with the drug. While blood studies may detect early peripheral blood changes, such as leukopenia, reticulocytopenia, or granulocytopenia, before they become irreversible, such studies cannot be relied on to detect bone marrow depression prior to development of aplastic anemia. To facilitate appropriate studies and observation during therapy, it is desirable that patients be hospitalized.

Brand Names: Canada
  • Chloromycetin Succinate
Pharmacologic Category
  • Antibiotic, Miscellaneous
Dosing: Adult

Usual dosage range: IV: 50 mg/kg/day in divided doses every 6 hours; an increased dosage up to 100 mg/kg/day may be required in some cases, but should be decreased as soon as possible (manufacturer's labeling). Maximum daily dose: 4 g/day (Ref).

Plague, treatment

Plague (Yersinia pestis), treatment:

Note: Consult public health officials for event-specific recommendations. Dose based on total body weight, including in patients with obesity and those who are underweight (Ref).

Bubonic, pharyngeal, pneumonic, or septicemic plague (alternative agent): IV: 12.5 mg/kg (maximum: 1 g /dose) every 6 hours for 10 to 14 days and for at least a few days after clinical resolution (Ref). For severe infections, a higher dose (25 mg/kg [maximum: 1 g/dose] every 6 hours) may be needed; reduce dose to 12.5 mg/kg (maximum: 1 g/dose) every 6 hours as soon as possible with clinical improvement (Ref).

Plague meningitis: Note: For initial treatment of patients who present with meningitis symptoms, use as part of an appropriate combination regimen; add chloramphenicol to existing antimicrobial regimen in patients who develop secondary plague meningitis.

IV: 25 mg/kg (maximum: 1 g/dose) every 6 hours; may reduce dose to 12.5 mg/kg (maximum: 1 g/dose) every 6 hours after clinical improvement. Recommended duration is 10 to 14 days and for at least a few days after clinical resolution when used for initial treatment (Ref); for secondary plague meningitis when chloramphenicol is added to existing therapy, continue entire regimen for an additional 10 days (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

There are no specific dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment may be necessary. Use with caution; monitor serum concentrations.

Dosing: Hepatic Impairment: Adult

There are no specific dosage adjustments provided in the manufacturer's labeling; however, dosage adjustments may be necessary. Use with caution; monitor serum concentrations.

Dosing: Older Adult

Refer to adult dosing.

Dosing: Pediatric

(For additional information see "Chloramphenicol: Pediatric drug information")

Note: Follow serum concentrations closely to monitor for toxicity. Use should be restricted to treatment of serious infections when less toxic drugs are ineffective (ie, resistance) or contraindicated. Chloramphenicol palmitate (oral formulation) is no longer available in the US; chloramphenicol sodium succinate (IV formulation) continues to be available.

Meningitis and nonmeningeal pneumococcal infections

Meningitis and nonmeningeal pneumococcal infections: Limited data available: Infants, Children, and Adolescents: IV: 18.75 to 25 mg/kg/dose every 6 hours; maximum daily dose: 4,000 mg/day (Ref).

Severe infections

Severe infections: Infants, Children, and Adolescents: IV: 12.5 to 25 mg/kg/dose every 6 hours; maximum daily dose: 4,000 mg/day (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

All patients: There are no dosage adjustments provided in the manufacturer's labeling; use with caution, reduced dosage and serum concentration monitoring is recommended.

Dosing: Hepatic Impairment: Pediatric

All patients: There are no dosage adjustments provided in the manufacturer's labeling; use with caution, reduced dosage and serum concentration monitoring is recommended.

Adverse Reactions

The following adverse drug reactions are derived from product labeling unless otherwise specified.

Postmarketing:

Dermatologic: Acute generalized exanthematous pustulosis (Lee 1999), skin rash (Haile 1977)

Gastrointestinal: Diarrhea (Haile 1977), glossitis (Haile 1977), nausea (Haile 1977), vomiting (Haile 1977)

Genitourinary: Hemoglobinuria (paroxysmal nocturnal)

Hematologic & oncologic: Aplastic anemia (Schmitt-Gräff 1981), bone marrow depression (Ferguson 1953), glucose-6-phosphate dehydrogenase deficiency anemia (Haile 1977), granulocytopenia (Poulton 1955), hypoplastic anemia (Todd 1954), immune thrombocytopenia (Poulton 1955), leukemia (Haile 1977), leukopenia (Haile 1977), neutropenia (Haile 1977), pancytopenia, sideroblastic anemia (Haile 1977), thrombocytopenia (Haile 1977)

Hypersensitivity: Hypersensitivity reaction (including angioedema) (Haile 1977)

Immunologic: Jarisch-Herxheimer reaction (Haile 1977)

Nervous system: Confusion (Levine 1970), delirium (Levine 1970), depression, encephalopathy (including asterixis, hallucination) (Levine 1970), headache

Ophthalmic: Optic atrophy (Keith 1964), optic neuritis (Keith 1964)

Respiratory: Neonatal cyanosis (gray syndrome) (Mulhall 1983)

Contraindications

Hypersensitivity to chloramphenicol or any component of the formulation; treatment of trivial or viral infections; bacterial prophylaxis

Warnings/Precautions

Concerns related to adverse effects:

• Gray syndrome: Characterized by cyanosis, abdominal distention, vasomotor collapse (often with irregular respiration), and death. Reaction appears to be associated with serum levels ≥50 mcg/mL (Powell 1982).

• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including Clostridium difficile–associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed >2 months postantibiotic treatment.

Disease-related concerns:

• Hepatic impairment: Use with caution; reduced dosage and serum concentration monitoring is recommended.

• Renal impairment: Use with caution; reduced dosage and serum concentration monitoring is recommended.

Special populations:

• Glucose 6-phosphate dehydrogenase deficiency: Use with caution in patients with glucose 6-phosphate dehydrogenase deficiency.

• Neonates: Use in premature and full-term neonates and infants has resulted in “gray syndrome" characterized by cyanosis, abdominal distention (with or without emesis), vasomotor collapse (often with irregular respiration), and death; progression of symptoms is rapid; prompt termination of therapy required. Reaction may result from drug accumulation caused by immature hepatic or renal function in neonates and infants.

Other warnings/precautions:

• Appropriate use: Avoid prolonged or repeated courses of treatment.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution Reconstituted, Intravenous [preservative free]:

Generic: 1 g (1 ea)

Generic Equivalent Available: US

Yes

Pricing: US

Solution (reconstituted) (Chloramphenicol Sod Succinate Intravenous)

1 g (per each): $58.38

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution Reconstituted, Intravenous:

Chloromycetin Succinate: 1 g (1 ea)

Administration: Adult

IV: For IV use only; do not administer IM. Can be administered IVP over at least 1 minute at a concentration of 100 mg/mL.

Administration: Pediatric

Parenteral:

IV push: Administer over at least 1 minute.

Intermittent IV infusion: Infuse over 30 to 60 minutes (Ref). In neonates, some centers have administered as an intermittent IV infusion over 15 minutes (Ref).

Hazardous Drugs Handling Considerations

Hazardous agent (NIOSH 2016 [group 2]).

Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.

NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).

Use: Labeled Indications

Serious bacterial infections: Treatment of serious infections, including cystic fibrosis exacerbations, bacterial meningitis, and bacteremia, caused by Haemophilus influenzae, Lymphogranuloma-psittacosis group, Rickettsia, Salmonella spp. (acute infections), and other susceptible organisms when less toxic agents are ineffective or contraindicated. Note: Development of resistance has limited utility of chloramphenicol in the treatment of Salmonella typhi; other agents are preferred (Dyson 2019).

Guideline recommendations: Chloramphenicol may be considered for use as an alternative agent to doxycycline in the treatment of tickborne rickettsial diseases (eg, Rocky Mountain spotted fever [RMSF]); however, epidemiologic studies suggest that chloramphenicol-treated patients with RMSF are at a higher risk of death compared to tetracycline-treated patients. In addition, chloramphenicol is not effective in the treatment of human ehrlichiosis or anaplasmosis, therefore, use with caution in the empiric treatment of tickborne rickettsial diseases (CDC [Biggs 2016]).

Medication Safety Issues
Sound-alike/look-alike issues:

Chloromycetin may be confused with chlorambucil, Chlor-Trimeton

Pediatric patients: High-risk medication:

KIDs List: Chloramphenicol, when used in neonates, is identified on the Key Potentially Inappropriate Drugs in Pediatrics (KIDs) list and should be avoided due to risk of gray baby syndrome unless serum concentration monitoring used (strong recommendation; high quality of evidence) (PPA [Meyers 2020]).

Metabolism/Transport Effects

Inhibits CYP2C9 (weak)

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii. Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy. Risk D: Consider therapy modification

BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). Risk X: Avoid combination

BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). Risk C: Monitor therapy

CefTAZidime: Chloramphenicol (Systemic) may diminish the therapeutic effect of CefTAZidime. Management: Consider using a different combination of antimicrobials, especially if bactericidal activity is desired. If these agents are combined, monitor for reduced antimicrobial effectiveness and/or therapeutic failure. Risk D: Consider therapy modification

Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics. Risk X: Avoid combination

CycloSPORINE (Systemic): Chloramphenicol (Systemic) may increase the serum concentration of CycloSPORINE (Systemic). Management: Cyclosporine dose reductions will likely be required with initiation of concurrent chloramphenicol. Monitor cyclosporine concentrations and response closely following initiation and/or discontinuation of chloramphenicol. Risk D: Consider therapy modification

Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics. Risk X: Avoid combination

Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). Risk X: Avoid combination

Fosphenytoin: May decrease the serum concentration of Chloramphenicol (Systemic). Fosphenytoin may increase the serum concentration of Chloramphenicol (Systemic). Chloramphenicol (Systemic) may increase the serum concentration of Fosphenytoin. Risk C: Monitor therapy

Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). Risk C: Monitor therapy

Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. Risk C: Monitor therapy

Myelosuppressive Agents: May enhance the myelosuppressive effect of Chloramphenicol (Systemic). Risk X: Avoid combination

PHENobarbital: May decrease the serum concentration of Chloramphenicol (Systemic). Chloramphenicol (Systemic) may increase the serum concentration of PHENobarbital. Risk C: Monitor therapy

Phenytoin: May decrease the serum concentration of Chloramphenicol (Systemic). Phenytoin may increase the serum concentration of Chloramphenicol (Systemic). Chloramphenicol (Systemic) may increase the serum concentration of Phenytoin. Risk C: Monitor therapy

Primidone: Chloramphenicol (Systemic) may increase serum concentrations of the active metabolite(s) of Primidone. Specifically, the concentrations of phenobarbital may be increased. Primidone may decrease the serum concentration of Chloramphenicol (Systemic). Risk C: Monitor therapy

RifAMPin: May increase the metabolism of Chloramphenicol (Systemic). Risk C: Monitor therapy

Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate. Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic. Risk D: Consider therapy modification

Sulfonylureas: Chloramphenicol (Systemic) may increase the serum concentration of Sulfonylureas. Risk C: Monitor therapy

Tacrolimus (Systemic): Chloramphenicol (Systemic) may increase the serum concentration of Tacrolimus (Systemic). Management: Reduce the tacrolimus dose and monitor tacrolimus whole blood concentrations frequently, beginning within 1 to 3 days of chloramphenicol initiation. Further tacrolimus dose adjustments should be guided by continued monitoring of tacrolimus levels. Risk D: Consider therapy modification

Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected. Management: Avoid use of live attenuated typhoid vaccine (Ty21a) in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose. Risk D: Consider therapy modification

Vitamin B12: Chloramphenicol (Systemic) may diminish the therapeutic effect of Vitamin B12. Risk C: Monitor therapy

Vitamin K Antagonists (eg, warfarin): CYP2C9 Inhibitors (Weak) may increase the serum concentration of Vitamin K Antagonists. Risk C: Monitor therapy

Pregnancy Considerations

Chloramphenicol crosses the placenta producing cord concentrations approaching maternal serum concentrations. An increased risk of teratogenic effects has not been associated with the use of chloramphenicol in pregnancy (Czeizel 2000; Heinonen 1977). "Gray Syndrome" has occurred in premature infants and newborns receiving chloramphenicol.

Chloramphenicol may be used as an alternative agent for the treatment of Rocky Mountain spotted fever in pregnant patients although caution should be used when administration occurs during the third trimester (CDC [Biggs 2016]).

Untreated plague (Yersinia pestis) infections in pregnant patients may result in hemorrhage (including postpartum hemorrhage), maternal and fetal death, preterm birth, and stillbirth. Limited data suggest maternal-fetal transmission of Y. pestis can occur if not treated. Pregnant patients should be treated for Y. pestis; parenteral antibiotics are preferred for initial treatment when otherwise appropriate. Chloramphenicol may be used as an alternative antibiotic for treating pregnant patients with bubonic, pharyngeal, pneumonic, or septicemic plague (doses at the lower end of the adult dosing range should be sufficient for most patients). Recommendations for treating pregnant patients with plague meningitis are the same as in nonpregnant patients. Chloramphenicol can be added to the antibiotic regimen for treatment of secondary plague meningitis (CDC [Nelson 2021]).

Breastfeeding Considerations

Chloramphenicol and its inactive metabolites are present in breast milk.

In general, antibiotics that are present in breast milk may cause non-dose–related modification of bowel flora. Infants exposed to chloramphenicol from breast milk should be monitored for GI disturbances, hemolysis, and jaundice (WHO 2002).

Chloramphenicol is well absorbed following oral administration; however, metabolism and excretion are highly variable in infants and children. The half-life is also significantly prolonged in low birth weight infants (Powell 1982).

Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends a decision be made to discontinue breastfeeding or to discontinue the drug, considering the importance of treatment to the mother. Other sources recommended avoiding use while breastfeeding, especially young infants (<34 weeks postconceptual age or <1 month of age) or when unusually large doses are needed (Atkinson 1988; Matsuda 1984; Plomp 1983; WHO 2002). Patients taking chloramphenicol for the treatment of plague (Y. pestis) should not breastfeed; if treatment with chloramphenicol is required, monitor the breastfed infant for GI distress, blood dyscrasias, and adequate nursing (CDC [Nelson 2021]).

Dietary Considerations

May have increased dietary need for riboflavin, pyridoxine, and vitamin B12. Some products may contain sodium.

Monitoring Parameters

CBC with differential (baseline and every 2 days during therapy); periodic hepatic and renal function tests; serum drug concentration as clinically indicated.

Reference Range

Therapeutic levels:

Pediatric:

Peak: Infants, Children, and Adolescents: 15 to 30 mcg/mL (SI: 46.3 to 92.7 mcmol/L) (Balbi 2004; Coakley 1992; Long 2012).

Trough: 5 to 15 mcg/mL (SI: 15.5 to 46.3 mcmol/L).

Adult:

Peak: 10 to 20 mcg/mL (SI: 30.9 to 61.8 mcmol/L) (Ambrose 1984; Hammet-Stabler 1998).

Trough: 5 to 10 mcg/mL (SI: 15.5 to 30.9 mcmol/L) (Ambrose 1984).

Timing of serum samples: Draw levels 0.5 to 1.5 hours after completion of IV dose (Hammet-Stabler 1998).

Mechanism of Action

Reversibly binds to 50S ribosomal subunits of susceptible organisms preventing amino acids from being transferred to growing peptide chains thus inhibiting protein synthesis

Pharmacokinetics (Adult Data Unless Noted)

Distribution: To most tissues and body fluids (Ambrose 1984); good CSF and brain penetration

CSF concentration with uninflamed meninges: 21% to 50% of plasma concentration

CSF concentration with inflamed meninges: 45% to 89% of plasma concentration

Chloramphenicol: Vd: 0.6 to 1 L/kg (Ambrose 1984)

Chloramphenicol succinate: Vd: 0.2 to 3.1 L/kg (Ambrose 1984)

Protein binding: Chloramphenicol: ~60%; decreased with hepatic or renal dysfunction and 30% to 40% in newborn infants (Ambrose 1984)

Metabolism:

Chloramphenicol: Hepatic to metabolites (inactive) (Ambrose 1984)

Chloramphenicol succinate: Hydrolyzed in the liver, kidney, and lungs to chloramphenicol (active) (Ambrose 1984)

Bioavailability:

Chloramphenicol: Oral: ~80% (Ambrose 1984)

Chloramphenicol succinate: IV: ~70%; highly variable, dependent upon rate and extent of metabolism to chloramphenicol (Ambrose 1984)

Half-life elimination:

Neonates: 1 to 2 days: 24 hours; 10 to 16 days: 10 hours

Chloramphenicol: Infants: Significantly prolonged (Powell 1982); Children 4 to 6 hours; Adults: ~4 hours (Ambrose 1984)

Hepatic disease: Prolonged (Ambrose 1984)

Excretion: Urine (~30% as unchanged chloramphenicol succinate in adults, 6% to 80% in children; 5% to 15% as chloramphenicol) (Ambrose 1984; Powell 1982)

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Apicol | Chloramex | Chlorampenicol | Chloromycetin | Chloroptic | Econochlor | Isopto fenicol | Kemicetine | Optichlor | Riachol | Spersanicol | Synthomycetine;
  • (AR) Argentina: Chloromycetin | Farmicetina | Klonalfenicol | Poenfenicol | Quemicetina;
  • (AT) Austria: Chloramphenicol agepha | Halomycetin | Kemicetin | Oleomycetin;
  • (AU) Australia: Apo chloramphenicol | Chloromycetin | Chlorsig | Cholfen | Ocuzo | Terry White Chemists Chloramphenicol;
  • (BD) Bangladesh: A-Phenicol | Aristophen | Chemophenicol | Chloramex | Chloraphenicol | Chlorphen | Cloram | Conicol | E col | Edrumycetin | Eyephen | Fionicol | Icol | Ocubac | Ocuclor | Ocuram | Ocutrex | Opsomycetin | Opsophenicol | Optabac | Optaphenicol | Opthacol | Optichlor | Otophenicol | Ramex | Ramicol | Ramphen | Reomphenicol | Spersanicol | Sq Mycetin | Stanophenicol | Staphenicol | Supraphen;
  • (BE) Belgium: Chloramphenicol erfa | Chloramphenicol thea pharma | Chloramphenicol viatris | Fenicol;
  • (BG) Bulgaria: Chlornitromycin;
  • (BR) Brazil: Amplobiotic | Clorafenil | Cloramed | Cloranfenicol | Cloranfenil | Clorex | Clorfenil | Feniclor | Fenicloran | Neo fenicol | Profenicol | Quemicetina | Sintomicetina | Visalmin;
  • (CI) Côte d'Ivoire: Oftalmolosa cusi chloramphenicol;
  • (CL) Chile: Chloromycetin | Cloranfenicol | Cloroptic | Gemitin | Kaph | Quemicetina | Spersanicol;
  • (CN) China: Ai ming | Chloramphenicol | Fu jie shu | Run shu;
  • (CO) Colombia: Chloromycetin | Clorafenicol | Cloranfenicol | Miroptic | Quemicetina | Spersanicol;
  • (DE) Germany: Aquamycetin | Chloramsaar n | Paraxin | Posifenicol | Thilocanfol c;
  • (DK) Denmark: Kloramfenikol viskoes dak;
  • (DO) Dominican Republic: Chloromycetin | Cloramfeni ofteno | Cloramfeni ungena | Cloramfenicol | Cloramicol | Cloramil | Cloranfenicol | Crisvin | Oftaclor | Optichlor | Sificetina;
  • (EC) Ecuador: Acromaxfenicol | Alfa cloromicol | Chloromycetin | Cloranfenicol | Cloroptic | Fenicol | Micoclorina | Spersanicol;
  • (EE) Estonia: Laevomycetin | Oftan Akvakol | Sificetina | Synthomycin;
  • (EG) Egypt: Adcocetine | Chloromycetin | Cidocetine | Epiphenicol | Isomiphenicol | Isoptofenicol | Levocol | Memcocetin | Memcocetine | Miphenicol | Ocuphenicol | Ophtamycetine | Ophtomycetine | Optocetine | Otophenicol;
  • (ES) Spain: Chloromycetin | Colircusi Cloramfenicol | Normofenicol | Oftalmolosa Cusi Cloramfenicol;
  • (ET) Ethiopia: Abchlor | Clorocil | Kloraxin;
  • (FI) Finland: Chloramphenicol orifarm | Chloromycetin | Klorita | Oculo klorita | Oftan Akvakol | Oftan Chlora | Oftan-kloramfenikol | Otichlora;
  • (FR) France: Cebenicol;
  • (GB) United Kingdom: Antibiotic Eye | Boots infected eyes | Brochlor | Chloramphen | Chloramphenic | Chloramphenic cox | Chloramphenicol almus | Chloramphenicol kent | Chloramphenicol sussex pharm | Chloromycetin | Chloromycetin p.d | Clorogen | Eykappo | Golden eye antibiotic | Kemicetine | Klorafect | Mollifeye | Ocumont | Optrex Bacterial Conjunctivitis | Optrex Infected Eye | Optrex infected eyes | Sno phenicol | Tubilux;
  • (GR) Greece: Chloranic | Kemicetine | Ursa fenol;
  • (GT) Guatemala: Alfer nicol;
  • (HK) Hong Kong: Aristophen | Chloment | Chloratets | Chloroph | Chlorsig | Elisca | Enicol | Europhen | Europhenicol | Isopto fenicol | Kemicetine | Lycofenicol | Lycophen | Neo phenicol | Opsaram | Optichlor | Optivis | Optomycin | Penicol | Phenicol | Silmycetin | Spersanicol | Vanafen | Venicol | Vyview top | Xepanicol;
  • (ID) Indonesia: Aromycetine | Bufacetin | Camicetine | Cendo fenicol | Cendo mycetine | Cendo mycine | Centraphenicol | Chloramet | Chloramex | Chloramidina | Chlorbiotic | Chloromycetin | Cloramidina | Colain | Colcetin | Colme | Colsancetine | Combicetin | Coromecytin | Decacetine | Denicol | Empeecetin | Enkacetyn | Erlamycetine | Farsycol | Fenicol | Grafacetin | Hufamycetin | Ikamicetin | Isotic salmicol | Itramycetine | Kalmicetin | Kalmicetine | Kemicetine | Kemocol | Kloramfenikol | Lanacetine | Librocetine | Magna Chloramphenicol | Mecocetin | Medichlor | Megachlor | Microtina | Neophenicol | Palmicol | Paraphenicol | Paraxin | Pharocetine | Reco | Recomycetin | Ribocine | Sakamycetin | Sinamycetin | Solachlor | Spersanicol | Suprachlor | Synthomycetine | Uniphenicol | Varicetine | Xepanicol;
  • (IE) Ireland: Chloromycetin;
  • (IL) Israel: Chlorphenicol | Phenicol | Synthomycine | Tarophenicol;
  • (IN) India: Acronicol | Amphen | Andrecin | Biochlor | Biophenecol | Cadimycetin | Chloraxin | Chlormet | Chlorocin | Chlorocol | Chloromycetin | Chlorosun | Chlorotin | Daclor | Dexoren | Enteromycetin | Fencol | I-chlor | Kemicetine | Kemicetine otologi | Klorum | Larmycetin | Loram | Lykacetin | Microcetin | O-mycin | Ocuchlor | Optichlor | Opticol | Otochlor | Paraxin | Phenicach | Ranphenicol | Ranquel | Reclor | Renicol | Starphenicol | Tycol | Vanmycetin | Vecol | Venez | Vitchol | Wocol;
  • (IQ) Iraq: Hayaphenicol | Samaphenicol;
  • (IT) Italy: Chemicetina | Chloromycetin | Cloramfen | Flogocyn | Ismicetina | Mycetin | Sificetina;
  • (JO) Jordan: Chloroptic | Isopto fenicol | Kemicetine | Phenicol | Snophenicol;
  • (JP) Japan: Chloramphe.maruko | Chloramphe.t nitto | Chloramphenicol t galen | Chloromycetin | Kemicetine | Paraxin | Sankyo | Synthomycetine;
  • (KE) Kenya: Axacrome | Biophenicol | Clomex | Cphen | Dawaphenicol | Elycetin | Eurocol | Ivychlornicol | Ivyphenicol | Mediphenicol | Metamycin | Ocumycin | Oramnicol | Rogophen | Salvaclor | Sq Mycetin | Xepanicol;
  • (KR) Korea, Republic of: Chlorampenicol | Chloramphenicol unimed | Helocetin | Nicol | Ocuchloram | Opticle | Penicol | Spersanicol | Synthomycetine;
  • (KW) Kuwait: Chloramphenicol Chibret | Chloroptic | Isopto fenicol | Oftalmolosa cusi chloramphenicol | Optichlor | Spersanicol;
  • (LB) Lebanon: Novamycetin | Paramycetin | Spersanicol;
  • (LT) Lithuania: Chlornitromycin | Isopto fenicol | Laevosin | Levomycetin | Synthomycin;
  • (LU) Luxembourg: Chloramphenicol erfa;
  • (LV) Latvia: Chlornitromycin | Isopto fenicol | Laevomycetinum | Laevosin | Levomycetin | Oftan Akvakol | Synthomycin;
  • (MA) Morocco: Cebenicol | Kemicetine;
  • (MX) Mexico: Abefen | Amfenil | Amsamicetin | Chloromycetin | Cloramfeni ofteno | Cloramfeni ungena | Cloramfenic genetica | Cloramfenicol | Cloramfenicol gi | Cloramfenicol gi s | Cloramfenicol landsteiner | Cloramfenicol Ultra | Cloramfenil | Clorampler | Cloran | Cloran-micron | Cloranfenicol | Cloranfenicol alpharma | Cloranfenicol Bruluagsa | Cloranfenicol mavi | Cloratenol | Clorfenil | Exacol | Fenicol oftalmico | Fenizzard | Infebye | Lebrocetin | Omycet | Palmiclor | Quemicetina | Solfranicol | Solvaris | Spersanicol | Westenicol;
  • (MY) Malaysia: Beaphenicol | Chloram | Chlorop | Enclor | Eucomycin | Kloraxin | Nicol | Shinacol | Spersanicol | Xepanicol;
  • (NG) Nigeria: Cafcol | Cedanicol | Chlorakris | Derm chloramphenicol | Hanbet chloramphenicol | Lorasin | Mediphenicol | Nuel chloramphenicol | Optomycin | Pecaf | Varmycin;
  • (NL) Netherlands: Chlooramfenic | Chlooramfenicol HPS | Chlooramfenicol ratiopharm | Chlooramfenicol thea | Chlooramfenicol-pos | Chloramphenic | Globenicol;
  • (NO) Norway: Kloramfenikol | Kloramfenikol aurora medical | Kloramfenikol naf | Kloramfenikol santen;
  • (NZ) New Zealand: Arrow chlorafast | Chlorafast | Chloromycetin | Chlorsig;
  • (PE) Peru: Chloromycetin | Cloramfenicol | Cloranfenicol | Clorin | Clorocid | Cloromisan | Cloroptic | Fenicol | Fenolyd | Queen cetina forte | Quemicetina | Sificetina | Spersanicol | Tifobiotic | Uniclor;
  • (PH) Philippines: Alphagram otic | Anpheclor | Benchlor | Bioclor | Biogenerics chloramphenicol | Biomycetin | Boie chloramphenicol | C-Phenicol | Celsus Chloramphenicol | Chloramed | Chloramin | Chloramol | Chlorampheni | Chloramphenicol Ad-drugstel pharm | Chloramphenicol Allied | Chloramphenicol Flamingo | Chloramphenicol Parl lab | Chloro s | Chloro V | Chlorolem | Chloromycetin | Chrisochlor | Clorstel | Compacol | Dli-chloramphenicol | Drexclo | Fen-alcon | Forastrol | Genphenil | Gerafen | Harvox | Intermycetin | Kemicetine | Knolcol | Lafayette chloramphenicol | Lorpican | Medichlor | Medimycetin | Medoptic | Metacol | Metrophenicol | Micromycetin | Neocol | Neophenicol c | Oliphenicol | Pediachlor | Penachlor | Perastan | Pharex chloramphenicol | Plivacol | Rielcetin | Ritemed Chloramphenicol | Roddenmycin | Samonef | Scanicol | Sensomed chloramphenicol | Siloram | Spersanicol | Sustachlor | Sydencetin | Ul chloramphenicol | Vamcetin | Vanchlor | Venimicetin | Zerruchlor;
  • (PK) Pakistan: Alklorafen | Bentaphen | Biomycin | Chlorin | Chlormax | Chloromycetin | Chloroptic | Cloramidina | Comycetin | Econochlor | Fenicol | Fenoptic | Geoclor | Invoclor | Medichlor | Medichlor plus | Neophenicol | Novophenicol | O-mycetin | Opchlor | Ophth chlor | Optachlor | Orbachlor | Remicol | Rexaphenicol | Santochlor | Schazomycetin | Sificetina | Spersanicol | Vasochlor | Vechlor | Vitachlor;
  • (PL) Poland: Brochlor | Detreomycina | O.c.chloramphenico;
  • (PR) Puerto Rico: Antibiotic | Chloromycetin | Chloroptic;
  • (PT) Portugal: Cloranfenicol | Clorocil | Dermimade cloranfenicol | Fenoptic | Kemicetine | Kemicetine oftalmo | Micetinoftalmina;
  • (PY) Paraguay: Cloranfenicol | Cloranfenicol dutriec | Cloranfenicol nicolich | Isopto fenicol | Lascamicetina | Novofenicol | Ofenicol | Spersanicol;
  • (QA) Qatar: Kemicetine;
  • (RO) Romania: Cloramfenicol | Otophenicol;
  • (RU) Russian Federation: Laevosin | Levomycetin | Levomycetin akos | Levomycetin ferein | Synthomycin;
  • (SA) Saudi Arabia: Chloromycetin | Chloroptic | Econochlor | Fenicol | Isopto fenicol | Optichlor | Phenicol | Riachol | Spersanicol;
  • (SE) Sweden: Chloromycetin | Isopto fenicol | Kloramfenikol ccs | Kloramfenikol santen;
  • (SG) Singapore: Beaphenicol | Enclor | Isopto fenicol | Minims chloramphenicol | Optomycin | Spersanicol | Xepanicol;
  • (SI) Slovenia: Chloramphenicol agepha | Otomycin;
  • (SL) Sierra Leone: Chloron;
  • (TH) Thailand: Ambricol | Antibi-otic ear drops | Archifen | Bemomycetin | Bemomycin | Chloment | Chlor-pyrad | Chloracil | Chloramdon | Chloramno | Chloramo | Chloramphenicol | Chloroph | Chloroptic | Cogetine | Comycin | Coracetin | Fenicol | Genercin | Koro | Levomycetin | Lichlorcin | Manocetin | Mycochlorin | Nicolmycetin | Opsaram | Optivis | Paraxin | Pharmacetin | Phen | Phenicol | Pisalin | Primacetin | Ramacol | Silmycetin | Skarnchlor | Unison | Uto chloramphenicol | Vanafen | Vanafen-s;
  • (TR) Turkey: Armisetin | Cebenicol | Devamycetin | Kemicetine;
  • (TW) Taiwan: Biomycin | C c mycin | C P | Chloment | Chloramphenical | Chlorlymin | Chlormycetin | Chlormycin | Chloromycetin | Hinicol | Inchlomycin | Isopto fenicol | Kemicetine | Keromycin | Kerromycin | Lomycin | Ocumicetin | Showen;
  • (UA) Ukraine: Chlorsig | Laevomycetin | Levomicin | Levomycetin | Synthomycin;
  • (UG) Uganda: Abchlor | Agophenol | Ascaf | Aurocol | Fomycetin | Ivychlornicol | Ivyphenocol | Kam chlor | Ocumycin | Renechlor;
  • (UY) Uruguay: Beyonas clor | Cloramfenicol | Fenicol | Isopto fenicol | Spersanicol;
  • (VE) Venezuela, Bolivarian Republic of: Chloromycetin | Cloftal | Cloramfenicol | Cloranfenicol;
  • (VN) Viet Nam: Agichloram | Clorocid tw3;
  • (ZA) South Africa: Chloramex | Chlorcol | Chlornicol | Chloromycetin | Chlorphen | Kloraxin | Micro-chloramphenicol | Rolab-chloramphenicol | Spersanicol;
  • (ZM) Zambia: Allphenicol | Amphen | Chlornicol | Chlorphen | Dexoren | Dicimycin | Fomycetin | Ivychlornicol | Ivyphenicol | Kloraxin | Metamycin | Opticol | Paracetin;
  • (ZW) Zimbabwe: Chlornicol
  1. <800> Hazardous Drugs—Handling in Healthcare Settings. United States Pharmacopeia and National Formulary (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.
  2. Ambrose PJ. Clinical pharmacokinetics of chloramphenicol and chloramphenicol succinate. Clin Pharmacokinet. 1984;9(3):222-238. [PubMed 6375931]
  3. American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. Red Book: 2018 Report of the Committee on Infectious Diseases. 31st ed. Itasca, IL: American Academy of Pediatrics; 2018.
  4. Aronoff GR, Bennett WM, Berns JS, et al, Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th ed. Philadelphia, PA: American College of Physicians; 2007.
  5. Atkinson HC, Begg EJ, Darlow BA. Drugs in human milk. Clinical pharmacokinetic considerations. Clin Pharmacokinet. 1988;14(4):217-240. [PubMed 3292101]
  6. Balbi HJ. Chloramphenicol: a review. Pediatr Rev. 2004;25(8):284-288. [PubMed 15286274]
  7. Biggs HM, Behravesh CB, Bradley KK, et al. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain Spotted Fever and Other Spotted Fever Group Rickettsioses, Ehrlichioses, and Anaplasmosis - United States. MMWR Recomm Rep. 2016;65(2):1-44. [PubMed 27172113]
  8. Bradley JS, Nelson JD, Kimberlin DK, et al, eds. Nelson's Pocket Book of Pediatric Antimicrobial Therapy. 19th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2012.
  9. Center for Disease Control and Prevention (CDC). Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted fever, ehrlichioses, and anaplasmosis - United States: a practical guide for physicians and other health-care and public health professionals. MMWR Recomm Rep. 2006. 55(RR-4):1-29. [PubMed 16572105]
  10. Chloramphenicol Sodium Succinate [prescribing information]. Lake Zurich, IL: Fresenius Kabi USA; October 2016.
  11. Coakley JC, Hudson I, Shann F, Connelly JF. A review of therapeutic monitoring of chloramphenicol in patients with Haemophilus influenzae meningitis. J Paediatr Child Health. 1992;28(3):249-253. [PubMed 1605978]
  12. Cocke JG Jr, “Chloramphenicol Optic Neuritis. Apparent Protective Effects of Very High Daily Doses of Pyridoxine and Cyanocobalamin,” Am J Dis Child, 1967, 114(4):424-6. [PubMed 6047242]
  13. Czeizel AE, Rockenbauer M, Sørensen HT, Olsen J. A population-based case-control teratologic study of oral chloramphenicol treatment during pregnancy. Eur J Epidemiol. 2000;16(4):323-327. [PubMed 10959939]
  14. Doona M and Walsh JB, “Use of Chloramphenicol as Topical Eye Medication: Time to Cry Halt?” BMJ, 1995, 310(6989):1217-8. [PubMed 7767184]
  15. Dyson ZA, Klemm EJ, Palmer S, Dougan G. Antibiotic resistance and typhoid. Clin Infect Dis. 2019;68(suppl 2):S165-S170. doi:10.1093/cid/ciy1111 [PubMed 30845331]
  16. Ferguson JW, Macfarlane JP. Depression of bone marrow activity after the use of chloramphenicol, with recovery. Glasgow Med J. 1953;34(1):22-25. [PubMed 13021568]
  17. Freundlich M, Cynamon H, Tamer A, et al, “Management of Chloramphenicol Intoxication in Infancy by Charcoal Hemoperfusion,” J Pediatr, 1983, 103(3):485-7. [PubMed 6886919]
  18. Haile CA. Chloramphenicol toxicity. South Med J. 1977;70(4):479-480. doi:10.1097/00007611-197704000-00034 [PubMed 850816]
  19. Hammett-Stabler CA and Johns T. Laboratory guidelines for monitoring of antimicrobial drugs. National Academy of Clinical Biochemistry. Clin Chem. 1998;44(5):1129-1140. [PubMed 9590397]
  20. Heinonen OP, Slone D, and Shapiro S. Birth Defects and Drugs in Pregnancy. Littleton, MA: Publishing Sciences Group; 1977.
  21. Keith CG. Optic atrophy induced by chloramphenicol. Br J Ophthalmol. 1964;48(10):567-570. doi:10.1136/bjo.48.10.567 [PubMed 14226042]
  22. Klaus JR, Knodel LC, Kavanagh RE. Administration guidelines for parenteral drug therapy. Part I: pediatric patients. J Pharm Technol. 1989;5(3):101-128. [PubMed 10318297]
  23. Kliegman RM and St. Geme J, eds. Nelson Textbook of Pediatrics. 21st ed. Philadelphia, PA: Saunders Elsevier; 2020.
  24. Kunin CM, Glazko AJ, and Finland M, “Persistence of Antibiotics in Blood of Patients With Acute Renal Failure. II. Chloramphenicol and Its Metabolic Products in the Blood of Patients With Severe Renal Failure Disease or Hepatic Cirrhosis,” J Clin Invest, 1959, 38(9):1498-508. [PubMed 14412753]
  25. Lee AY, Yoo SH. Chloramphenicol induced acute generalized exanthematous pustulosis proved by patch test and systemic provocation. Acta Derm Venereol. 1999;79(5):412-413. doi:10.1080/000155599750010571 [PubMed 10494741]
  26. Levine PH, Regelson W, Holland JF. Chloramphenicol-associated encephalopathy. Clin Pharmacol Ther. 1970;11(2):194-199. doi:10.1002/cpt1970112194 [PubMed 5416851]
  27. Long S, Pickering L, eds. Bacterial meningitis: antimicrobial therapy. Principles and practice of pediatric infectious diseases. 4th ed. Elsevier Inc; 2012.
  28. Long SS, Prober CG, Fischer M, eds. Bacterial meningitis: antimicrobial therapy. Principles and practice of pediatric infectious diseases. 5th ed. Elsevier Inc; 2018.
  29. Matsuda S. Transfer of antibiotics into maternal milk. Biol Res Pregnancy Perinatol. 1984;5(2):57-60. [PubMed 6743732]
  30. Messick CR and Pendland SL, “In Vitro Activity of Chloramphenicol Alone and in Combination With Vancomycin, Ampicillin, or RP 59500 (Quinupristin/Dalfopristin) Against Vancomycin-Resistant Enterococci,” Diagn Microbiol Infect Dis, 1997, 29(3):203-5.
  31. Meyers RS, Thackray J, Matson KL, et al. Key Potentially Inappropriate Drugs in Pediatrics: The KIDs List. J Pediatr Pharmacol Ther. 2020;25(3):175-191. [PubMed 32265601]
  32. Moffa M and Brook I; Tetracyclines, Glycylcyclines, and Chloramphenicol. In: Bennett JE, Dolin R, and Blaser MJ, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 8th ed. Philadelphia, PA: Elsevier, 2015.
  33. Montoro A, Cao A, Ordoqui E, et al, “Contact Sensitivity to Chloramphenicol,” J Allergy Clin Immunol, 1995, 95:291.
  34. Mulhall A, de Louvois J, Hurley R. Chloramphenicol toxicity in neonates: its incidence and prevention. Br Med J (Clin Res Ed). 1983;287(6403):1424-1427. doi:10.1136/bmj.287.6403.1424 [PubMed 6416440]
  35. Mulhall A, de Louvois J, Hurley R. Efficacy of chloramphenicol in the treatment of neonatal and infantile meningitis: a study of 70 cases. Lancet. 1983;1(8319):284-287. [PubMed 6130304]
  36. Nahata MC and Powell DA, “Bioavailability and Clearance of Chloramphenicol After Intravenous Chloramphenicol Succinate,” Clin Pharmacol Ther, 1981, 30(3):368-72. [PubMed 7273601]
  37. Nelson CA, Meaney-Delman D, Fleck-Derderian S, Cooley KM, Yu PA, Mead PS; The Centers for Disease Control and Prevention. Antimicrobial treatment and prophylaxis of plague: recommendations for naturally acquired infections and bioterrorism response. MMWR Recomm Rep. 2021;70(3):1-27. doi:10.15585/mmwr.rr7003a1 [PubMed 34264565]
  38. Plomp TA, Thiery M, and Maes RA, "The Passage of Thiamphenicol and Chloramphenicol Into Human Milk After Single and Repeated Oral Administration," Vet Hum Toxicol, 1983, 25(3):167-72. [PubMed 6868331]
  39. Poulton EM. Thrombocytopenic purpura during chloramphenicol therapy. Br Med J. 1955;2(4931):106. doi:10.1136/bmj.2.4931.106 [PubMed 14378658]
  40. Powell DA, Nahata MC. Chloramphenicol: new perspectives on an old drug. Drug Intell Clin Pharm. 1982;16(4):295-300. [PubMed 040026]
  41. Prober CG, Stevenson DK, Benitz WE. The use of antibiotics in neonates weighing less than 1200 grams. Pediatr Infect Dis J. 1990; 9:111-121. [PubMed 2179837]
  42. Rajchgot P, Prober CG, Soldin S, et al. Initiation of chloramphenicol therapy in the newborn infant. J Pediatr. 1982; 101:1018-1021. [PubMed 7143156]
  43. Rajchgot P, Prober CG, Soldin SJ, et.al. Toward optimization of therapy in the neonate. Clinical Pharmacology and Therapeutics. 1983;33(5):551-555. [PubMed 6839629]
  44. Ramilo O, Kinane BT, and McCracken GH Jr, “Chloramphenicol Neurotoxicity,” Pediatr Infect Dis J, 1988, 7(5):358-9. [PubMed 3380586]
  45. Refer to manufacturer's labeling.
  46. Schmitt-Gräff A. Chloramphenicol-induced aplastic anemia terminating with acute nonlymphocytic leukemia. Acta Haematol. 1981;66(4):267-268. doi:10.1159/000207133 [PubMed 6800194]
  47. Smilack JD, Wilson WR, and Cockerill FR 3d, “Tetracyclines, Chloramphenicol, Erythromycin, Clindamycin, and Metronidazole,” Mayo Clin Proc, 1991, 66(12):1270-80. [PubMed 1749296]
  48. Stout J. Clinical manifestations, diagnosis, and treatment of plague (Yersinia pestis infection). Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed March 17, 2022.
  49. Todd RM. The treatment of hypoplastic anaemia after chloramphenicol. Arch Dis Child. 1954;29(148):575-577. doi:10.1136/adc.29.148.575 [PubMed 13218741]
  50. Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004;39(9):1267-1284. [PubMed 15494903]
  51. Tunkel AR, Wispelwey B, and Scheld M, “Bacterial Meningitis: Recent Advances in Pathophysiology and Treatment,” Ann Intern Med, 1990, 112(8):610-23. [PubMed 2183667]
  52. US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. https://www.cdc.gov/niosh/docs/2016-161/default.html. Updated September 2016. Accessed October 5, 2016.
  53. Vozeh S, Schmidlin O, and Taeschner W, “Pharmacokinetic Drug Data,” Clin Pharmacokinet, 1988, 15(4):254-82. [PubMed 3359738]
  54. Weiss CF, Glazko AJ, Weston JK. Chloramphenicol in the newborn infant. New Engl J Med. 1960;262(16):787-794. [PubMed 13843700]
  55. World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the Eleventh WHO Model List of Essential Drugs. 2002. Available at https://apps.who.int/iris/handle/10665/62435
  56. Yoshikawa TT, “Antimicrobial Therapy for the Elderly Patient,” J Am Geriatr Soc, 1990, 38(12):1353-72. [PubMed 2254575]
  57. Yunis AA, “Chloramphenicol: Relation of Structure to Activity and Toxicity,” Annu Rev Pharmacol Toxicol, 1988, 28:83-100. [PubMed 3289495]
Topic 9241 Version 483.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟